This page discusses the use of hormonal therapy for the treatment of breast cancer. For a thorough review of hormonal therapy for cancer treatment, please see the hormonal therapy treatment monograph.
Hormones are chemical messengers that regulate specific body functions, such as reproduction. They are produced by various glands in the body and enter the bloodstream where they travel to other tissues and exert their influence. Hormonal therapy is used in cancer treatment to augment or interfere with the activity of certain hormones that can influence the growth of tumors.
Hormonal therapy is designed to take advantage of the fact that many breast cancers are hormone sensitive. Breast cancer that is hormone sensitive may be estrogen receptor positive or progesterone receptor positive depending on which hormone they react to. The hormones, estrogen or progesterone, are able to bind to cancer cells and stimulate growth and division. Hormonal therapy prevents the binding of these hormones to the cancer cells. This stops the cells from growing and, in doing so, prevents or delays breast cancer recurrence. It can also lower the risk of a second, independent breast cancer.
Tissue testing can determine if a cancer is sensitive to hormones. Cancers that are not hormone receptors positive do not appear to benefit from hormonal therapy, either to prevent recurrence, or to prevent second cancers.
While the vast majority of women who have hormone-sensitive breast cancer will benefit from hormonal therapy, there may be times when the risks may outweigh the potential benefits. Your doctor will help you weigh the risks and benefits.
The goal of hormonal therapy is to prevent hormones from attaching to cancer cells and helping cancer grow. This may be done in a number of ways:
Hormonal therapy may include:
A commonly used selective estrogen receptor modulator (SERM) is raloxifene. This medication is used to treat osteoporosis. In postmenopausal women with osteoporosis who have been treated with raloxifene, this medication has been shown to reduce the risk of breast cancer.
Raloxifene is not yet approved for use in breast cancer treatment. Its benefits, compared to tamoxifen, are being evaluated in the STAR prevention trial. Some reports have found a lower risk of uterine cancer among women taking raloxifene as compared with women taking tamoxifen. The development of uterine cancer is known to be influenced by estrogen-like activity. Raloxifene has been associated with an increased risk of blood clots.
Aromatase inhibitors may be more effective than tamoxifen in both early and advanced stages of breast cancer. Aromatase inhibitors work by inhibiting the conversion of androgens into estrogens. Androgens are commonly referred to as male hormones, but they are found in both men and women. A small amount of androgen is continuously converted into estrogen by the enzyme aromatase. Aromatase inhibitors block the action of aromatase, leaving less estrogen available to stimulate estrogen receptors on cancer cells.
Aromatase inhibitors are used primarily in postmenopausal women. These drugs are generally taken by mouth in tablet form on a daily basis.
Drugs in this class include:
When compared to tamoxifen, anastrazole was equally as or more effective than tamoxifen for:
The primary side effect of aromatase inhibitors is an increased risk of osteoporosis (including bone thinning and hip fractures). Therefore, women who use aromatase inhibitors need to have their bone densities measured on a regular basis, and may need medications to improve bone density such as bisphosphonates, calcium, and vitamin D. Exercise also helps with bone density.
Estrogen receptor down-regulators bind to estrogen receptors on cancer cells and block the receptors so that estrogen cannot enter the cancer cell. This is a complicated process, as certain drugs can act as blockers in one tissue or situation and act like estrogen in other tissues or situations. Two drugs in this class are tamoxifen and fulvestrant.
Tamoxifen is used for both treatment and prevention of breast cancer. It attaches to the estrogen receptor which prevents the estrogen from binding to the cancer cell. Tamoxifen is a standard treatment for women with hormone receptor-positive breast cancer.
Possible side effects and complications associated with tamoxifen include the following:
Fulvestrant, like tamoxifen, attaches to the estrogen receptor. However, unlike tamoxifen, it destroys the receptor, thereby blocking all estrogen activity. It is given once per month by intramuscular injection for as long as it is beneficial in the treatment of advanced or metastatic breast cancer.
Luteinizing hormone (LH) is secreted from cells in the pituitary gland and stimulates the ovaries to produce and secrete estrogen. Luteinizing hormone-releasing hormone (LHRH) agonists are used to block the action of LH. Doing so blocks ovarian production of estrogen. LHRH agonists are used for chemical ovarian ablation.
Androgens, progesterone, and progestational agents have been used to treat advanced, hormone-sensitive breast cancer when other medications have not been effective.
Ovarian ablation is the destruction or removal of ovarian tissue. The reduction of tissue decreases the amount of hormones being produced in the body. It is useful for pre- and perimenopausal women only.
The most common method used is called chemical ovarian ablation. Goserelin is a medication that reduces production of luteinizing hormone (LH) from the pituitary gland, which leads to a reduction of estrogen. This can result in shrinking the tumor or slowing the progression of cancer.
Goserelin is injected under the skin of the upper abdomen every 28 days. This treatment is used primarily in premenopausal women with early stage receptor-positive breast cancer.
Goserelin can be used alone or with other forms of treatment. Further study is needed to determine if ovarian ablation is more effective when combined with other treatments or when given alone.
Ovarian ablation may also be done with surgery or radiation. Chemical ovarian ablation is the preferred method because, unlike the other options, it is temporary, and fertility may be restored after treatment. Fertility restoration depends on many factors, including whether or not other treatments have caused permanent damage.
The following side effects may occur with hormonal treatments:
A variety of treatments are available to help manage side effects including medication, lifestyle changes, and alternative treatments. In some cases, hormonal therapy treatment may be adjusted to reduce severe side effects. The earlier the side effects are addressed, the more likely they will be controlled with a minimum of discomfort.
Breast cancer. Merck Manual Professional Version website. Available at: https://www.merckmanuals.com/professional/gynecology-and-obstetrics/breast-disorders/breast-cancer. Updated January 2018. Accessed December 21, 2018.
Breast cancer in women. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T113654/Breast-cancer-in-women. Updated November 26, 2018. Accessed December 21, 2018.
Endocrine therapy for early and locally advanced breast cancer. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T114433/Endocrine-therapy-for-early-and-locally-advanced-breast-cancer. Updated November 30, 2018. Accessed December 21, 2018.
Endocrine therapy for metastatic breast cancer. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T921934/Endocrine-therapy-for-metastatic-breast-cancer. Updated November 26, 2018. Accessed December 21, 2018.
Goserelin. National Cancer Institute website. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/goserelinacetate. Updated July 25, 2018. Accessed December 21, 2018.
Hormone therapy for breast cancer. American Cancer Society website. Available at: https://www.cancer.org/cancer/breast-cancer/treatment/hormone-therapy-for-breast-cancer.html. Updated September 26, 2017. Accessed December 21, 2018.
Treatment of hot flashes in patients with breast cancer. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T901190/Treatment-of-hot-flashes-in-patients-with-breast-cancer. Updated January 8, 2018. Accessed December 21, 2018.
Treatment option overview. National Cancer Institute website. Available at: https://www.cancer.gov/types/breast/patient/breast-treatment-pdq#section/_185. Updated October 19, 2018. Accessed December 21, 2018.
Last reviewed June 2017 by by EBSCO Medical Review Board Mohei Abouzied, MD, FACP Last Updated: 11/2/2015